Technology

Voyager Therapeutics

$8.67
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.17 (+2.00%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell VYGR and other stocks, options, and ETFs commission-free!

About VYGR

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA. The listed name for VYGR is Voyager Therapeutics, Inc. Common Stock.

CEO
G. Andre Turenne
Employees
185
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
324.83M
Price-Earnings Ratio
8.17
Dividend Yield
—
Average Volume
471.03K
High Today
$8.80
Low Today
$8.53
Open Price
$8.75
Volume
583.66K
52 Week High
$14.62
52 Week Low
$6.26

Collections

VYGR Earnings

-$0.81
$0.22
$1.24
$2.27
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 3, After Hours

You May Also Like

NNGRY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure